Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Serum-Free Avonex in RRMS
NCT00912860Phase 2Completed
- Sponsor
- Biogen
- Start
- Jan 2003
- Primary completion
- Dec 2004
- Modality
- Cytokines & Interferons
01
Overview
A Phase 2 trial of interferon beta-1a in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Started Jan 2003; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00912860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00912860.